A randomized, double-blind, placebo-controlled, multicenter Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN101 injection in non-diabetic overweight or obese subjects
Latest Information Update: 09 Sep 2025
At a glance
- Drugs MWN 101 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Most Recent Events
- 09 Sep 2025 New trial record